Ranitidinebismuthcitrate
- CAS NO.:128345-62-0
- Empirical Formula: C19H30N4O10S
- Molecular Weight: 506.53
- MDL number: MFCD00891318
- EINECS: 1308068-626-2
- SAFETY DATA SHEET (SDS)
- Update Date: 2024-10-28 23:16:16
What is Ranitidinebismuthcitrate?
Description
Ranitidine bismuth citrate, a novel salt formed from ranitidine and a bismuth citrate complex, is a new agent introduced in the United Kingdom for the treatment of duodenal and benign gastric ulcers, for eradication of Helicobacfer pylori, and for prevention of relapse of duodenal ulcer when administered in combination with an antibiotic such as clarithromycin or amoxicillin. Ranitidine is a potent histamine H2-receptor antagonist with ability to inhibit gastric acid secretion. Other type of agents such as tripotassium dicitrato bismuthate exert their therapeutic effects in peptic ulceration by providing a protective coating to the ulcer crater, stimulating endogenous prostaglandin production, and inhibiting pepsin activity. More significantly, they inhibit micro-organism Helicobacfer pylori, a prevalent, specifically human pathogen associated with gastritis and gastric ulcers. The title compound possesses a novel combination of properties of the above two types of drugs and displays excellent therapeutic efficacy in clinical studies. Ranitidine bismuth citrate is being investigated for use in gastritis and non-ulcerating dyspepsia, acute healing of gastrointestinal ulcer and in prevention of the recurrence of peptic ulcer disease.
Originator
Glaxo Wellcome (United Kingdom)
The Uses of Ranitidinebismuthcitrate
Antagonist (to histamine H2receptors).
brand name
Tritec (GlaxoSmithKline);Pylorid.
Hazard
A poison by ingestion.
Mechanism of action
Ranitidine bismuth citrate has been developed for combination therapy with antibiotics for eradication of H.p. Depending on the co-prescription, eradication ranged from 15 to 92 % in an intention-to-treat analysis . It is claimed to combine the antisecretory action of ranitidine with the antimicrobial and gastroprotective actions of bismuth.
Safety information for Ranitidinebismuthcitrate
Abamectin manufacturer
Monopoly Innovations Pvt. Ltd.
New Products
4-Aminotetrahydropyran-4-carbonitrile Hydrochloride (R)-3-Aminobutanenitrile Hydrochloride 4-AMINO-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HCL 4-(Dimethylamino)tetrahydro-2H-pyran-4-carbonitrile 3-((Dimethylamino)methyl)-5-methylhexan-2-one oxalate 1,4-Dioxa-8-azaspiro[4.5]decane 5-Bromo-2-nitropyridine Nimesulide BP Aceclofenac IP/BP/EP Diclofenac Sodium IP/BP/EP/USP Mefenamic Acid IP/BP/EP/USP Ornidazole IP Diclofenac Potassium SODIUM AAS SOLUTION ZINC AAS SOLUTION BUFFER SOLUTION PH 10.0(BORATE) GOOCH CRUCIBLE SINTERED AQUANIL 5 BERYLLIUM AAS SOLUTION 2-Bromo-1-(bromomethyl)-3-chloro-5-nitrobenzene 2-Bromo-3-nitroaniline N-(3-Hydroxypropyl)-N-methylacetamide 3-Bromo-6-chloropyridazine 4-ethyl-3-nitrobenzoic acidRelated products of tetrahydrofuran
You may like
-
Ranitidine bismuth citrate 128345-62-0 98%View Details
128345-62-0 -
1-Methyl-6-oxo-1,6-dihydropyridazine-3-carbonitrile 98%View Details
99903-60-3 -
1823368-42-8 98%View Details
1823368-42-8 -
2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%View Details
1307449-08-6 -
Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%View Details
25408-95-1 -
2-Chloro-5-fluoro-1-methoxy-3-methylbenzene 98%View Details
1805639-70-6 -
1784294-80-9 98%View Details
1784294-80-9 -
Lithium ClavulanateView Details
61177-44-4